Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Men and women, ages 18-75 inclusive
Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment
Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) \[Cyclosporine A (CsA) or Tacrolimus (TAC)\] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids
Stable renal function for 12 weeks prior to enrollment without new onset proteinuria
Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 \[Modification of Diet in Renal Disease study (MDRD) 4-formula\]
You may not be if
Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown
History of acute rejection (AR) within 3 months prior to enrollment
History of antibody mediated rejection
Positive T-cell lymphocytotoxic cross match
Proteinuria \>1 g/day or \>0.5 g/day if diabetic
Clareo Health | A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
